Marshall Wace, LLP Lineage Cell Therapeutics, Inc. Transaction History

Marshall Wace, LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.2 - $1.53 $22,233 - $28,347	18,528 Added 49.92%	55,646 $83,000
Q4 2022 Feb 14, 2023	SELL	$1.02 - $1.5 $6,843 - $10,063	-6,709 Reduced 15.31%	37,118 $43,000
Q3 2022 Nov 14, 2022	BUY	$1.13 - $1.77 $49,524 - $77,573	43,827 New	43,827 $50,000
Q2 2021 Aug 13, 2021	BUY	$2.17 - $3.0 $405,659 - $560,820	186,940 New	186,940 $533,000

120

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $95.1M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.